Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Summit Therapeutics (SMMT) EBITDA Margin (2016 - 2022)

Summit Therapeutics filings provide 7 years of EBITDA Margin readings, the most recent being 9742.73% for Q3 2022.

  • Quarterly EBITDA Margin fell 817955.0% to 9742.73% in Q3 2022 from the year-ago period, while the trailing twelve-month figure was 271352.27% through Jun 2023, down 26717354.0% year-over-year, with the annual reading at 11131.63% for FY2022, 632207.0% down from the prior year.
  • EBITDA Margin hit 9742.73% in Q3 2022 for Summit Therapeutics, down from 6800.85% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 70.2% in Q3 2018 and bottomed at 41887.72% in Q2 2021.
  • Average EBITDA Margin over 5 years is 6737.43%, with a median of 5340.47% recorded in 2020.
  • The largest annual shift saw EBITDA Margin tumbled -3286948bps in 2021 before it surged 3508687bps in 2022.
  • Summit Therapeutics' EBITDA Margin stood at 1385.05% in 2018, then tumbled by -348bps to 6205.65% in 2019, then rose by 11bps to 5524.86% in 2020, then crashed by -86bps to 10300.4% in 2021, then grew by 5bps to 9742.73% in 2022.
  • Per Business Quant, the three most recent readings for SMMT's EBITDA Margin are 9742.73% (Q3 2022), 6800.85% (Q2 2022), and 9262.8% (Q1 2022).